Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial

T van der Veer, JM de Koning Gans, GJ Braunstahl, ALP Pieters, JMW van den Berg, RAS Hoek, LSJ Kamphuis, M Bakker, AVF Dubois, JGJV Aerts, MM van der Eerden
European Respiratory Journal 2023; DOI: 10.1183/13993003.00186-2023
T van der Veer
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
2Department of Respiratory Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
8Shared first authorship
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T van der Veer
  • For correspondence: t.vanderveer@erasmusmc.nl
JM de Koning Gans
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
3Department of Medicine, University of Otago, Christchurch, New Zealand
8Shared first authorship
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for JM de Koning Gans
GJ Braunstahl
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
2Department of Respiratory Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for GJ Braunstahl
ALP Pieters
4Department of Radiology, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JMW van den Berg
5Department of Respiratory Medicine, Haga Teaching Hospital, The Hague, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAS Hoek
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
6Department of Respiratory Medicine, Bravis Hospital, Bergen op Zoom, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for RAS Hoek
LSJ Kamphuis
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Bakker
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AVF Dubois
7Department of Respiratory Medicine, Admiraal De Ruyter Ziekenhuis, Goes, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JGJV Aerts
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MM van der Eerden
1Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Extract

Bronchiectasis is a chronic inflammatory condition of the airways with high symptom burden, including chronic cough [1]. The current management strategy includes identifying aetiology, comorbidity, and treatable traits. The role of inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) in treatment is uncertain. ICS use is only advised for patients with coexisting asthma or COPD [1, 2]. However, up to 53.1% of bronchiectasis patients use ICS or ICS/LABA, with a third having no asthma or COPD diagnosis, according to a recent EMBARC analysis (European Multicentre Bronchiectasis Audit and Research Collaboration) [3]. A study by Martinez-Garcia et al. showed that ICS/LABA can alleviate cough in bronchiectasis patients compared to ICS alone [4]. In our multicentre, randomised, double-blind trial comparing beclomethasone-formoterol versus placebo, we hypothesised that ICS/LABA could reduce cough complaints in bronchiectasis patients without asthma or COPD.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: T van der Veer declares support for the present study from Chiesi Pharmaceuticals (provision of study medication; no payments and no other support provided).

Conflict of interest: JM de Koning Gans declares support for the present study from Chiesi Pharmaceuticals (provision of study medication; no payments and no other support provided).

Conflict of interest: GJ Braunstahl declares grants or contract funds paid to their institution by GlaxoSmithKline, AstraZeneca and Sanofi; consulting fees from Sanofi, GlaxoSmithKline, ALK Abello and AstraZeneca; and payment or honoraria from Chiesi, ALK Abello, GlaxoSmithKline and TEVA, all in the 36 months prior to manuscript submission; and that they hold unpaid roles as the Chair of the Asthma Section of NVALT and an editorial board member of NTvAAKI.

Conflict of interest: LSJ Kamphuis declares payment from Chiesi for developing e-learning materials about non-CF bronchiectasis, in the 36 months prior to manuscript submission.

Conflict of interest: JGJV Aerts declares payment of speaker's fees from Eli Lilly, Merck Sharp & Dohme and BIOCAD; and participation on Data Safety Monitoring Boards or Advisory Boards for Eli Lilly, Amphera, BIOCAD and Merck Sharp & Dohmr, all in the 36 months prior to manuscript submission. In addition, they have patents planned, issued or pending with Pamgene and Amphera, and hold stock in Amphera. They also declare board membership of the International Association for the Study of Lung Cancer.

Conflict of interest: MM van der Eerden declares support for the present study from Chiesi Pharmaceuticals (provision of study medication; no payments and no other support provided).

Conflict of interest: All other authors declare no competing interests

  • Received January 31, 2023.
  • Accepted May 9, 2023.
  • Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial
T van der Veer, JM de Koning Gans, GJ Braunstahl, ALP Pieters, JMW van den Berg, RAS Hoek, LSJ Kamphuis, M Bakker, AVF Dubois, JGJV Aerts, MM van der Eerden
European Respiratory Journal Jan 2023, 2300186; DOI: 10.1183/13993003.00186-2023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial
T van der Veer, JM de Koning Gans, GJ Braunstahl, ALP Pieters, JMW van den Berg, RAS Hoek, LSJ Kamphuis, M Bakker, AVF Dubois, JGJV Aerts, MM van der Eerden
European Respiratory Journal Jan 2023, 2300186; DOI: 10.1183/13993003.00186-2023
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Radiographic score in TB and relationship to therapy and bacillary load
  • Translated impact on carbon footprint from choice of inhaled therapy
  • Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease - a randomised, double-blind, placebo-controlled, crossover trial
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society